Erratum: The late effects of childhood cancer therapy (Pediatrics (March 2007) 119, (554-568) doi: 10.1542/peds.2006-2826);The late effects of childhood cancer therapy

Pediatrics

Volumn 119, Issue 3, 2007, Pages 554-568

  Dickerman, Joseph D ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer survivors; Cancer therapy; Childhood cancer; Late effects

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; MELPHALAN; METHOTREXATE; PROCARBAZINE; STEROID; TENIPOSIDE; THIOTEPA; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ARTERY INJURY; BLADDER CANCER; BLADDER INJURY; BONE CANCER; BONE INJURY; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CATARACT; CHILDHOOD CANCER; COGNITIVE DEFECT; DRUG MEGADOSE; GONAD DYSFUNCTION; HEARING LOSS; HEART AFTERLOAD; HEART ARRHYTHMIA; HEART INFARCTION; HEART INJURY; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONTRACTILITY; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; KIDNEY INJURY; LEUKOENCEPHALOPATHY; LUNG FIBROSIS; LUNG INJURY; LUNG TOXICITY; METASTASIS; MUSCLE ATROPHY; MYELODYSPLASTIC SYNDROME; OBESITY; PERICARDIAL DISEASE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIATION PNEUMONIA; REVIEW; SHORT STATURE; SIDE EFFECT; SKIN CANCER; STROKE; THYROID CANCER; TOOTH DISEASE; VALVULAR HEART DISEASE;

EID: 33947132078     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2007-0753     Document Type: Erratum

References (133)

1. Friedman DL, Meadows AT. Late effects of childhood cancer therapy. Pediatr Clin North Am. 2002;49:1083-1106
2. Hampton T. Cancer survivors need better care: new report makes recommendations. JAMA. 2005;294:2959-2960
3. Hampton T. Cancer treatment's trade-off: years of added life can have long-term costs. JAMA. 2005;294:167-168
4. Meadows AT. Pediatric cancer survivors: past history and future challenges. Curr Probl Cancer. 2003;27:112-126
5. Hewitt M, Simone J. Childhood Cancer Survivorship: Improving Care and Quality of Life. Washington, DC: National Academies Press; 2003
6. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572-1582
7. Barr RD, Greenberg ML. Cancer surveillance and control in adolescents: similarities and contrasts between Canada and the United States. Pediatr Blood Cancer. 2006;46:273-277
8. Oeffinger KC, Mertens AC, Hudson MM, et al. Health care of young adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Fam Med. 2004;2:61-70
9. Aziz NM, Oeffinger KC, Brooks S, Turoff AJ. Comprehensive long-term follow-up programs for pediatric cancer survivors. Cancer. 2006;107:841-848
10. Arvidson J, Soderhall S, Eksborg S, Bjork O, Kreuger A. Medical follow-up visits in adults 5-25 years after treatment for childhood acute leukaemia, lymphoma or Wilms' tumour. Acta Paediatr. 2006;95:922-928
11. Sklar CA. Overview of the effects of cancer therapies: the nature, scale and breadth of the problem. Acta Paediatr Suppl. 1999;88(433):1-4
12. Stevens MC, Mahler H, Parkes S. The health status of adult survivors of cancer in childhood. Eur J Cancer. 1998;34:694-698
13. Park ER, Li FP, Liu Y, et al. Health insurance coverage in survivors of childhood cancer: the Childhood Cancer Survivor Study. J Clin Oncol. 2005;23:9187-9197
14. de Boer AG, Verbeek JH, van Dijk FJ. Adult survivors of childhood cancer and unemployment: a meta-analysis. Cancer. 2006;107:1-11
15. CureSearch. Risk-based guidelines for pediatric cancer survivors. Available at: www.survivorshipguidelines.org. Accessed December 21, 2006
16. Kremer LC, Caron HN. Anthracycline cardiotoxicity in children. N Engl J Med. 2004;351:120-121
17. Hinkle AS, Proukou CB, Deshpande SS, et al. Cardiotoxicity caused by chemotherapy. In: Wallace WH, Green DM, eds. Late Effects of Childhood Cancer. London, United Kingdom: Arnold; 2004:85-100
18. Paulides M, Kremers A, Stohr W, et al. Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the late effects surveillance system (LESS). Pediatr Blood Cancer. 2006;46:489-495
19. Lipshultz SE. Exposure to anthracyclines during childhood causes cardiac injury. Semin Oncol. 2006;33(3 suppl 8):S8-S14
20. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol. 2005;131:561-578
21. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol. 2005;23:7685-7696
22. Berry GJ, Jorden M. Pathology of radiation and anthracycline cardiotoxicity. Pediatr Blood Cancer. 2005;44:630-637
23. Adams MJ, Lipshultz SE. Pathophysiology of anthracycline-and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer. 2005;44:600-606
24. Bowers DC, Mulne AF, Reisch JS, et al. Nonperioperative strokes in children with central nervous system tumors. Cancer. 2002;94:1094-1101
25. Bowers DC, Liu Y, Leisenring W, et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006;24:5277-5282
26. Chow AY, Chin C, Dahl G, Rosenthal DN. Anthracyclines cause endothelial injury in pediatric cancer patients: a pilot study. J Clin Oncol. 2006;24:925-928
27. Weiner DJ, Maity A, Carlson CA, Ginsberg JP. Pulmonary function abnormalities in children treated with whole lung irradiation. Pediatr Blood Cancer. 2006;46:222-227
28. Marina N, Sharis C, Tarbell N. Respiratory complications. In: Wallace WH, Green DM, eds. Late Effects of Childhood Cancer. London, United Kingdom: Arnold; 2004:114-122
29. Mertens AC, Yasui Y, Liu Y, et al. Pulmonary complications in survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study. Cancer. 2002;95:2431-2441
30. Oeffinger KC, Hudson MM. Long-term complications following childhood and adolescent cancer: foundations for providing risk-based health care for survivors. CA Cancer J Clin. 2004;54:208-236
31. Sostman HD, Matthay RA, Putman CE, Smith GJ. Methotrexate-induced pneumonitis. Medicine (Baltimore). 1976;55:371-388
32. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-122
33. Waghorn DJ. Overwhelming infection in asplenic patients: current best practice preventive measures are not being followed. J Clin Pathol. 2001;54:214-218
34. Kaplinsky C, Spirer Z. Post-splenectomy antibiotic prophylaxis: unfinished story - to treat or not to treat? Pediatr Blood Cancer. 2006;47:740-741
35. Guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Working Party of the British Committee for Standards in Haematology Clinical Haematology Task Force. BMJ. 1996;312:430-434
36. American Academy of Pediatrics, Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics. 2000;106:362-366
37. Bessho F, Kinumaki H, Yokota S, Hayashi Y, Kobayashi M, Kamoshita S. Liver function studies in children with acute lymphocytic leukemia after cessation of therapy. Med Pediatr Oncol. 1994;23:111-115
38. McIntosh S, Davidson DL, O'Brien RT, et al. Methotrexate hepatotoxicity in children with leukemia. J Pediatr. 1977;90:1019-1021
39. Hudson M. Hepatic complications. In: Wallace WH, Green DM, eds. Late Effects of Childhood Cancer. London, United Kingdom: Arnold; 2004:170-175
40. Paul IM, Sanders J, Ruggiero F, Andrews T, Ungar D, Eyster ME. Chronic hepatitis C virus infections in leukemia survivors: prevalence, viral load, and severity of liver disease. Blood. 1999;93:3672-3677
41. Sevinir B, Meral A, Gunay U, Ozkan T, Ozuysal S, Sinirtas M. Increased risk of chronic hepatitis in children with cancer. Med Pediatr Oncol. 2003;40:104-110
42. Castellino S, Lensing S, Riely C, et al. The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive cohort. Blood. 2004;103:2460-2466
43. Bardi E, Olah AV, Bartyik K, et al. Late effects on renal glomerular and tubular function in childhood cancer survivors. Pediatr Blood Cancer. 2004;43:668-673
44. Smith GR, Thomas PR, Ritchey M, Norkool P. Long-term renal function in patients with irradiated bilateral Wilms tumor. National Wilms' Tumor Study Group. Am J Clin Oncol. 1998;21:58-63
45. McCune JS, Friedman DL, Schuetze S, Blough D, Magbulos M, Hawkins DS. Influence of age upon Ifosfamide-induced nephrotoxicity. Pediatr Blood Cancer. 2004;42:427-432
46. Skinner R. Renal damage. In: Wallace WH, Green DM, eds. Late Effects of Childhood Cancer. London, United Kingdom: Arnold; 2004:125-137
47. Yeung CK, Ward HC, Ransley PG, Duffy PG, Pritchard J. Bladder and kidney function after cure of pelvic rhabdomyosarcoma in childhood. Br J Cancer. 1994;70:1000-1003
48. Stillwell TJ, Benson RC Jr. Cyclophosphamide-induced hemorrhagic cystitis: a review of 100 patients. Cancer. 1988;61:451-457
49. Brade WP, Herdrich K, Varini M. Ifosfamide: pharmacology, safety and therapeutic potential. Cancer Treat Rev. 1985;12:1-47
50. Rehman Q, Lane NE. Effect of glucocorticoids on bone density. Med Pediatr Oncol. 2003;41:212-216
51. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000;18:1570-1593
52. Stein E, Shane E. Secondary osteoporosis. Endocrinol Metab Clin North Am. 2003;32:115-134, vii
53. Kaste SC, Rai SN, Fleming K, et al. Changes in bone mineral density in survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2006;46:77-87
54. Nachman JB. My aching bones: skeletal complications of acute lymphoblastic leukemia. Pediatr Blood Cancer. 2006;46:1
55. Pietila S, Sievanen H, Ala-Houhala M, Koivisto AM, Liisa Lenko H, Makipernaa A. Bone mineral density is reduced in brain tumour patients treated in childhood. Acta Paediatr. 2006;95:1291-1297
56. Fletcher BD. Effects of pediatric cancer therapy on the musculoskeletal system. Pediatr Radiol. 1997;27:623-636
57. Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000;85:3227-3232
58. Metzger ML, Hudson MM, Somes GW, et al. White race as a risk factor for hypothyroidism after treatment for pediatric Hodgkin's lymphoma. J Clin Oncol. 2006;24:1516-1521
59. Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med. 1991;325:599-605
60. Gregory JW, Reilly JJ. Body composition and obesity. In: Wallace WH, Green DM, eds. Late Effects of Childhood Cancer. London, United Kingdom: Arnold; 2004:147-161
61. Oeffinger KC, Mertens AC, Sklar CA, et al. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2003;21:1359-1365
62. Reilly JJ, Ventham JC, Newell J, Aitchison T, Wallace WH, Gibson BE. Risk factors for excess weight gain in children treated for acute lymphoblastic leukaemia. Int J Obes Relat Metab Disord. 2000;24:1537-1541
63. Bongers ME, Francken AB, Rouwe C, Kamps WA, Postma A. Reduction of adult height in childhood acute lymphoblastic leukemia survivors after prophylactic cranial irradiation. Pediatr Blood Cancer. 2005;45:139-143
64. Darzy KH, Gleeson HK, Shalet SM. Growth and neuroendocrine consequences. In: Wallace WH, Green DM, eds. Late Effects of Childhood Cancer. London, United Kingdom: Arnold; 2004:189-211
65. Brownstein CM, Mertens AC, Mitby PA, et al. Factors that affect final height and change in height standard deviation scores in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2004;89:4422-4427
66. Critchley HO, Thomson AB, Wallace WH. Ovarian and uterine function and reproductive potential. In: Wallace WH, Green DM, eds. Late Effects of Childhood Cancer. London, United Kingdom: Arnold; 2004:225-238
67. Thomson AB, Wallace WH, Sklar C. Testicular function. In: Wallace WH, Green DM, eds. Late Effects of Childhood Cancer. London, United Kingdom: Arnold; 2004:239-256
68. Edge B, Holmes D, Makin G. Sperm banking in adolescent cancer patients. Arch Dis Child. 2006;91:149-152
69. Wallace WH, Thomson AB. Preservation of fertility in children treated for cancer. Arch Dis Child. 2003;88:493-496
70. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917-2931
71. Spiegler BJ, Kennedy K, Maze R, et al. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate. J Clin Oncol. 2006;24:3858-3864
72. Hudson MM, Mertens AC, Yasui Y, et al. Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JAMA. 2003;290:1583-1592
73. Recklitis CJ, Lockwood RA, Rothwell MA, Diller LR. Suicidal ideation and attempts in adult survivors of childhood cancer. J Clin Oncol. 2006;24:3852-3857
74. Tercyak KP, Donze JR, Prahlad S, Mosher RB, Shad AT. Multiple behavioral risk factors among adolescent survivors of childhood cancer in the Survivor Health and Resilience Education (SHARE) Program. Pediatr Blood Cancer. 2006;47:825-830
75. Recklitis C, O'Leary T, Diller L. Utility of routine psychological screening in the childhood cancer survivor clinic. J Clin Oncol. 2003;21:787-792
76. Spoudeas H. Disturbance of the hypothalamic-pituitary thyroid axis. In: Wallace WH, Green DM, eds. Late Effects of Childhood Cancer. London, United Kingdom: Arnold; 2004:212-224
77. Sklar CA, Constine LS. Chronic neuroendocrinological sequelae of radiation therapy. Int J Radiat Oncol Biol Phys. 1995;31:1113-1121
78. Rose SR, Schreiber RE, Kearney NS, et al. Hypothalamic dysfunction after chemotherapy. J Pediatr Endocrinol Metab. 2004;17:55-66
79. Duffner PK. Long-term neurologic consequences of CNS therapy. In: Wallace WH, Green DM, eds. Late Effects of Childhood Cancer. London, United Kingdom: Arnold; 2004:5-17
80. Jeng MR, Feusner J. Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2001;18:137-142
81. Ober M, Beaverson K, Abramson D. Ocular complications. In: Wallace WH, Green DM, eds. Late Effects of Childhood Cancer. London, United Kingdom: Arnold; 2004:35-48
82. Bertolini P, Lassalle M, Mercier G, et al. Platinum compoundrelated ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol. 2004;26:649-655
83. Shearer S. Hearing Impairment. In: Wallace WH, Green DM, eds. Late Effects of Childhood Cancer. London, United Kingdom: Arnold; 2004:49-54
84. van den Berg JH, Beijnen JH, Balm AJ, Schellens JH. Future opportunities in preventing cisplatin induced ototoxicity. Cancer Treat Rev. 2006;32:390-397
85. Sonis AL. Craniofacial development, teeth and salivary glands. In: Wallace WH, Green DM, eds. Late Effects of Childhood Cancer. London, United Kingdom: Arnold; 2004:176-185
86. Alberth M, Kovalecz G, Nemes J, et al. Oral health of long-term childhood cancer survivors. Pediatr Blood Cancer. 2004;43:88-90
87. Argani P, Lae M, Ballard ET, et al. Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol. 2006;24:1529-1534
88. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood Cancer Survivor Study. J Natl Cancer Inst. 2001;93:618-629
89. Benton E, Tidman M. Cutaneous complications. In: Wallace WH, Green DM, eds. Late Effects of Childhood Cancer. London, United Kingdom: Arnold; 2004:321-331
90. Perkins JL, Liu Y, Mitby PA, et al. Nonmelanoma skin cancer in survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2005;23:3733-3741
91. Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease [published correction appears in JAMA. 2003;290:1318]. JAMA. 2003;290:465-475
92. Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol. 2002;20:3484-3494
93. Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol. 2003;21:4386-4394
94. Yahalom J. Breast cancer after Hodgkin disease: hope for a safer cure. JAMA. 2003;290:529-531
95. Wendland MM, Tsodikov A, Glenn MJ, Gaffney DK. Time interval to the development of breast carcinoma after treatment for Hodgkin disease. Cancer. 2004;101:1275-1282
96. Hill DA, Gilbert E, Dores GM, et al. Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood. 2005;106:3358-3365
97. Lin HM, Teitell MA. Second malignancy after treatment of pediatric Hodgkin disease. J Pediatr Hematol Oncol. 2005;27:28-36
98. Guibout C, Adjadj E, Rubino C, et al. Malignant breast tumors after radiotherapy for a first cancer during childhood. J Clin Oncol. 2005;23:197-204
99. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst. 1993;85:25-31
100. Wolden SL, Hancock SL, Carlson RW, Goffinet DR, Jeffrey SS, Hoppe RT. Management of breast cancer after Hodgkin's disease. J Clin Oncol. 2000;18:765-772
101. Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005;23:8469-8476
102. Sigurdson AJ, Ronckers CM, Mertens AC, et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet. 2005;365:2014-2023
103. de Vathaire F, Hardiman C, Shamsaldin A, et al. Thyroid carcinomas after irradiation for a first cancer during childhood. Arch Intern Med. 1999;159:2713-2719
104. Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. Arch Intern Med. 1996;156:2165-2172
105. Hegedus L. Clinical practice: the thyroid nodule. N Engl J Med. 2004;351:1764-1771
106. Crom DB, Kaste SC, Tubergen DG, Greenwald CA, Sharp GB, Hudson MM. Ultrasonography for thyroid screening after head and neck irradiation in childhood cancer survivors. Med Pediatr Oncol. 1997;28:15-21
107. Metzger ML, Howard SC, Hudson MM, et al. Natural history of thyroid nodules in survivors of pediatric Hodgkin lymphoma. Pediatr Blood Cancer. 2006;46:314-319
108. Acharya S, Sarafoglou K, LaQuaglia M, et al. Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence. Cancer. 2003;97:2397-2403
109. Collini P, Massimino M, Leite SF, et al. Papillary thyroid carcinoma of childhood and adolescence: a 30-year experience at the Istituto Nazionale Tumori in Milan. Pediatr Blood Cancer. 2006;46:300-306
110. Ng A, Taylor GM, Eden OB. Treatment-related leukaemia: a clinical and scientific challenge. Cancer Treat Rev. 2000;26:377-391
111. Bhatia S. Epidemiology. In: Wallace WH, Green DM, eds. Late Effects of Childhood Cancer. London, United Kingdom: Arnold; 2004:57-69
112. Woodard P, Barfield R, Hale G, et al. Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. Pediatr Blood Cancer. 2006;47:931-935
113. Davies SM. Therapy-related leukemia associated with alkylating agents. Med Pediatr Oncol. 2001;36:536-540
114. + cells and remain stable after clonal expansion. Blood. 2005;105:2124-2131
115. Relling MV, Boyett JM, Blanco JG, et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood. 2003;101:3862-3867
116. Le Deley MC, Leblanc T, Shamsaldin A, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a casecontrol study by the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol. 2003;21:1074-1081
117. Long ZB, Oeffinger KC, Brooks SL, et al. Incidence and clinical relevance of abnormal complete blood counts in long-term survivors of childhood cancer. Cancer. 2006;106:1634-1640
118. Engelhardt M, Ozkaynak MF, Drullinsky P, et al. Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy. Leukemia. 1998;12:13-24
119. Hawkins MM, Wilson LM, Burton HS, et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst. 1996;88:270-278
120. Spunt SL, Rodriguez-Galindo C, Fuller CE, et al. Ewing sarcoma-family tumors that arise after treatment of primary childhood cancer. Cancer. 2006;107:201-206
121. Bassal M, Mertens AC, Taylor L, et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006;24:476-483
122. Bhatia S, Sklar C. Second cancers in survivors of childhood cancer. Nat Rev Cancer. 2002;2:124-132
123. Neglia JP, Robison LL, Stovall M, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2006;98:1528-1537
124. Peterson KM, Shao C, McCarter R, MacDonald TJ, Byrne J. An analysis of SEER data of increasing risk of secondary malignant neoplasms among long-term survivors of childhood brain tumors. Pediatr Blood Cancer. 2006;47:83-88
125. Leiper AD. Non-endocrine late complications of bone marrow transplantation in childhood: part I. Br J Haematol. 2002;118:3-22
126. Leiper AD. Non-endocrine late complications of bone marrow transplantation in childhood: part II. Br J Haematol. 2002;118:23-43
127. Brennan BM, Shalet SM. Endocrine late effects after bone marrow transplant. Br J Haematol. 2002;118:58-66
128. Ades L, Guardiola P, Socie G. Second malignancies after allogeneic hematopoietic stem cell transplantation: new insight and current problems. Blood Rev. 2002;16:135-146
129. Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors [published correction appears in J Clin Oncol. 2003;21:3181]. J Clin Oncol. 2003;21:1352-1358
130. Goldsby RE, Ablin AR. Surviving childhood cancer; now what? Controversies regarding long-term follow-up. Pediatr Blood Cancer. 2004;43:211-214
131. Hinkle AS, Proukou C, French CA, et al. A clinic-based, comprehensive care model for studying late effects in long-term survivors of pediatric illnesses. Pediatrics. 2004;113:1141-1145
132. Rowland JH, Hewitt M, Ganz PA. Cancer survivorship: a new challenge in delivering quality cancer care. J Clin Oncol. 2006;24:5101-5104
133. Hewitt M, Greenfield S, Stovall E, eds. From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC: National Academies Press; 2006. Available at: www.iom.edu/?id=30869. Accessed December 21, 2006